With its innovative Clinical Trials Network, influential annual meeting and high-impact journals, SNMMI encourages and facilitates research and science for the nuclear medicine and molecular imaging field. Learn more.

Clinical Trials Network

The Clinical Trials Network (CTN) provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Our Mission is to advance the use of molecular imaging agents in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new radiopharmaceuticals to regulatory approval. Programs developed over the past 5 years include a comprehensive registry of qualified imaging sites and radiopharmaceutical manufacturers, a robust scanner validation program, access to standardized imaging protocols and a very strong clinical research education curriculum.


  • January 14, 2022SNMMI Statement: Possible Effect of Omicron Infection on FDG PET/CT Scans
    SNMMI's COVID-19 Task Force makes new recommendations for FDG PET/CT and FDG PET/MR in relation to the Omicron variant.
  • January 12, 2022SNMMI Reacts to CMS Coverage Decision on New Alzheimer’s Therapy
    On January 11, CMS announced that it proposes to cover FDA-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease under CED in CMS-approved randomized controlled trials. SNMMI reacts.
  • January 11, 2022PET/CT Artificial Intelligence Model Ideal for Predicting Risk of Future Heart Attack
    When assessed together in an AI model, coronary F-18 NaF uptake on PET and quantitative coronary plaque characteristics on CT angiography were found to provide risk prediction superior to that of clinical data alone.
  • January 7, 2022JNM Publishes Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging
    SNMMI and peer medical groups have issued AUC for PSMA PET imaging. Published in the January issue of JNM, the criteria are the product of an international multidisciplinary panel of expert healthcare providers.
  • January 4, 2022This Month in JNM
    Discussions with Leaders – Nuclear medicine in Australia … State of the Art – a-emitter labeling review … Hot Topics – Imaging ICI-induced myocarditis … Focus on MI – Molecular breast imaging … SNMMI appropriate use criteria for PSMA PET imaging … Featured: 68Ga-FAPI PET/CT in fILD and LC … 18F-FAraG imaging of CNS T cells … and more.
  • December 14, 2021A Call to Action to Ensure Federal Funding for Scientific Research
    SNMMI and the Academy of Radiology and Biomedical Imaging Research have partnered to urge Congress to pass an FY22 appropriations package that supports the National Institutes of Health (NIH) and biomedical imaging, while stopping the use of harmful continuing resolutions (CRs).
  • December 6, 2021JNM Supplement Addresses Radiopharmaceutical Dosimetry for Cancer Therapy
    Can the tailoring of drug dosage improve the effectiveness of radiopharmaceutical therapy (RPT) for cancer patients? JNM has issued a new supplement addressing both the rapid progress and the challenges in applying patient-specific radiation dosimetry to guide RPT.
  • December 1, 2021This Month in JNM
    In December JNM: Discussion with leaders—Mark Mintun, MD … State of the Art—Combination PSMA theranostics … Hot Topics—Embolization of liver-dominant NETs … Focus on MI—21st century imaging biomarkers … Featured—Dual-phase 18F-FPCIT PET in PD … Modifying 223Ra distribution … and more.

Preclinical Imaging

CMIIT’s mission is to engage the molecular imaging community and leverage the SNMMI infrastructure to advance the adoption of emerging molecular imaging technologies and probes in preclinical and clinical applications. One of the goals is to develop educational resources for a “translational researcher”. CMIIT will provide researchers with needed education and training on the “nuts and bolts” of translating and transitioning an agent or technique from pre-clinical research into the clinical practice such as tracer development, equipment, and funding.

The Nuclear Medicine Clinical Trial Group, LLC

Under the auspices of the Society of Nuclear Medicine and Molecular Imaging, the Nuclear Medicine Clinical Trial Group(NMCTG) assists industry partners and academic investigators in managing clinical research activities.  Its goals include ensuring quality imaging is conducted in drug or diagnostic clinical trials and providing training for molecular imaging professionals performing clinical research. Many of the programs established under the Clinical Trials Network, such as its robust Education Program, provide support to the NMCTG to help carry out its mission.